Effects of PPARγ Ligands on Leukemia
Peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RARs), members of the nuclear receptor superfamily, are transcription factors that regulate a variety of important cellular functions. PPARs form heterodimers retinoid X receptor (RXR), an obligate heterodimeric partner...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2012/483656 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850237672738521088 |
|---|---|
| author | Yoko Tabe Marina Konopleva Michael Andreeff Akimichi Ohsaka |
| author_facet | Yoko Tabe Marina Konopleva Michael Andreeff Akimichi Ohsaka |
| author_sort | Yoko Tabe |
| collection | DOAJ |
| description | Peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RARs), members of the nuclear receptor superfamily, are transcription factors that regulate a variety of important cellular functions. PPARs form heterodimers retinoid X receptor (RXR), an obligate heterodimeric partner for other nuclear receptors. Several novel links between retinoid metabolism and PPAR responses have been identified, and activation of PPAR/RXR expression has been shown to increase response to retinoids. PPARγ has emerged as a key regulator of cell growth and survival, whose activity is modulated by a number of synthetic and natural ligands. While clinical trials in cancer patients with thiazolidinediones (TZD) have been disappointing, novel structurally different PPARγ ligands, including triterpenoids, have entered clinical arena as therapeutic agents for epithelial and hematopoietic malignancies. Here we shall review the antitumor advances of PPARγ, alone and in combination with RARα ligands in control of cell proliferation, differentiation, and apoptosis and their potential therapeutic applications in hematological malignancies. |
| format | Article |
| id | doaj-art-1317caf06bf844e19ecf3e9a1e43873f |
| institution | OA Journals |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-1317caf06bf844e19ecf3e9a1e43873f2025-08-20T02:01:41ZengWileyPPAR Research1687-47571687-47652012-01-01201210.1155/2012/483656483656Effects of PPARγ Ligands on LeukemiaYoko Tabe0Marina Konopleva1Michael Andreeff2Akimichi Ohsaka3Department of Clinical Laboratory Medicine, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, JapanDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USADepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USADepartment of Transfusion Medicine and Stem Cell Regulation, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, JapanPeroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RARs), members of the nuclear receptor superfamily, are transcription factors that regulate a variety of important cellular functions. PPARs form heterodimers retinoid X receptor (RXR), an obligate heterodimeric partner for other nuclear receptors. Several novel links between retinoid metabolism and PPAR responses have been identified, and activation of PPAR/RXR expression has been shown to increase response to retinoids. PPARγ has emerged as a key regulator of cell growth and survival, whose activity is modulated by a number of synthetic and natural ligands. While clinical trials in cancer patients with thiazolidinediones (TZD) have been disappointing, novel structurally different PPARγ ligands, including triterpenoids, have entered clinical arena as therapeutic agents for epithelial and hematopoietic malignancies. Here we shall review the antitumor advances of PPARγ, alone and in combination with RARα ligands in control of cell proliferation, differentiation, and apoptosis and their potential therapeutic applications in hematological malignancies.http://dx.doi.org/10.1155/2012/483656 |
| spellingShingle | Yoko Tabe Marina Konopleva Michael Andreeff Akimichi Ohsaka Effects of PPARγ Ligands on Leukemia PPAR Research |
| title | Effects of PPARγ Ligands on Leukemia |
| title_full | Effects of PPARγ Ligands on Leukemia |
| title_fullStr | Effects of PPARγ Ligands on Leukemia |
| title_full_unstemmed | Effects of PPARγ Ligands on Leukemia |
| title_short | Effects of PPARγ Ligands on Leukemia |
| title_sort | effects of pparγ ligands on leukemia |
| url | http://dx.doi.org/10.1155/2012/483656 |
| work_keys_str_mv | AT yokotabe effectsofppargligandsonleukemia AT marinakonopleva effectsofppargligandsonleukemia AT michaelandreeff effectsofppargligandsonleukemia AT akimichiohsaka effectsofppargligandsonleukemia |